In another investigator-initiated phase II trial (ClinicalTrials.gov identifier: NCT02507492), three people with severe obesity due to LEPR deficiency were administered setmelanotide.62 The results of this trial indicate significant and sustained reductions in hyperphagia and body weight, which were sustained over the observation period of 45–61 weeks. This evidence concerns the gene LEPR and hyperinsulinemic hypoglycemia, familial, 4.